Sign in

NCT07810335Not yet recruiting

Evaluation of FlowMod System While Intermittently Partially Occluding Vena Cava Blood Flow in Subjects With ADHF

An Evaluation of the FLOWMod System to Occlude Vena Cava Blood Flow in Subjects With Acute Decompensated Heart Failure

Source: ClinicalTrials.gov · Last updated 9 Sept 2026

Brief summary (registry, in English)

FLOW-HF will assess the impact of intermittent partial occlusion of the SVC and/or IVC, the cardiac filling pressure and the difference of effects between the two occlusion locations (SVC and IVC) using the FlowMod flow modulating device on select parameters in subjects experiencing ADHF (Acute Decompensated Heart Failure)

Status (registry)
Not yet recruiting
Study type
Interventional
Enrollment
30 (estimated)
First submitted
24 Aug 2026
Start date
5 Sept 2026
Primary completion date
15 Feb 2027
Lead sponsor
FlowMod, Inc.
NCT number
NCT07810335

What you commit to

  • Study type: Interventional
  • Planned participants: 30
  • From 5 Sept 2026 to the primary completion date, 15 Feb 2027
  • 4 sites in 2 countries
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • ACS or MI within 30 days prior to enrollment
  • Subjects receiving mechanical circulatory support
  • Subjects with inadequate jugular vein access due to prior jugular vein thrombosis or indwelling chronic ports or catheters or presence of vena cava filter
  • Subjects with pacemaker or defibrillator leads placed through the SVC ≤ 3 months prior to procedure
  • Prior carotid interventions (stenting or endarterectomy)
  • Subjects receiving hemodialysis or planning to within 30 days

Other illness

  • Active myocardial ischemia (MI) or acute coronary syndrome (ACS)
  • Subjects with history of cardiac transplant
  • Inability to tolerate right heart catheterization
  • Subjects who have a history of major or minor stroke or TIA ≤ 12 months or subjects with a history of stroke \> 12 months who have a residual neurological deficit
  • Hypersensitivity or contraindication to latex
  • Subjects with history of CABG ≤ 3 months
  • Subjects with known coagulopathy or any blood disorders
  • Severe carotid disease
  • History of DVT (\<6m or requiring ongoing anticoagulants for either DVT or hypercoagulable state)
  • History of pulmonary embolism
  • Right ventricular failure based on an RA:PCWP ratio of \>0.8, PAPi\<1.0; or TAPSE\<10

Lab values

  • Subjects with Ejection Fraction (EF) of \<15%

Other

  • Severe valvular stenosis
  • Severe aortic valve regurgitation
  • Subjects with a contraindication to contrast dye
  • Contraindication to unfractionated heparin
  • Unable to provide informed consent
  • Subjects with impaired decision-making capacity
  • Pregnant subjects
  • Right atrial/ventricular thrombus
  • Sustained ventricular tachycardia (\>10 beats) within 24 hours and/or ventricular fibrillation within 24 hours
  • Rapid atrial fibrillation (HR\>120 bpm)
  • Systolic blood pressure \< 90 mm Hg
  • Inability to interrupt the anticoagulation treatment
  • Subjects with life expectancy of \<30 days or known risk for mortality within 90 days
  • SVC/IVC stenosis
  • SVC/IVC diameter not suitable for balloon inflations
  • Planned LVAD device placement
  • Subject on \>2 inotropes or escalating inotropes during pre-enrollment hospitalization

Who the study is looking for

  • Male or females between 18 and 85 years of age
  • NYHA Class III-IV heart failure
  • Stage C-D systolic heart failure
  • Clinically indicated for right heart catheterization
  • Volume overload status of the subject confirmed by the presence of at least 1 or more of the following congestion signs or symptoms assessed by physical examination or x-ray: Peripheral edema, rales, jugular venous distension, abdominal distension or evidence of congestion by chest x-ray
  • Subjects with RAP \>10 mmHg
  • Subjects with PCWP \>18 mmHg
  • Subjects with inadequate diuresis defined as total urinary output over the most recent 8 hours prior to enrollment of \<1200 mL while on a stable dose of diuretics
  • Subjects with eGFR \>30mL/min/1.732

Age in the registry: 18 years to 85 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (4)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Tbilisi Heart and Vascular Clinic
Coordinator of this site? Confirm its status
TbilisiGeorgiaUnknown status
Tbilisi Heart Center
Coordinator of this site? Confirm its status
TbilisiGeorgiaUnknown status
Republican Specialized Center of Cardiology
Coordinator of this site? Confirm its status
TashkentUzbekistanUnknown status
Ezgu Niyat Medical Clinic
Coordinator of this site? Confirm its status
TashkentUzbekistanUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.